BGC > Product Search > Mivebresib

Description :
Mivebresib is a BET inhibitor with potential antineoplastic activity. It disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo. Mivebresib is also a MYC and the TMPRSS2-ETS fusion proteins inhibitor. Mivebresib can inhibit cell growth in susceptible tumors.

• Molecular Weight :459.47
• Purity :98%

Molecular Formula :
C22H19F2N3O4S
Canonical SMILES :
CCS(=O)(=O)Nc1ccc(Oc2ccc(F)cc2F)c(c1)C3=CN(C)C(=O)c4[nH]ccc34
InChI :
1S/C22H19F2N3O4S/c1-3-32(29,30)26-14-5-7-19(31-20-6-4-13(23)10-18(20)24)16(11-14)17-12-27(2)22(28)21-15(17)8-9-25-21/h4-12,25-26H,3H2,1-2H3
InChIKey :
RDONXGFGWSSFMY-UHFFFAOYSA-N
Solubility :
Soluble in DMSO
Appearance :
Powder
Application :
anti-tumor
Storage : -20°C Freezer
Synonyms :
ABBV-075; ABBV 075; ABBV075; Mivebresib;N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide

More details are to be found here